Gotti, E <br/><br/>
Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.  [electronic resource] 

 -  Clinical transplantation  Dec 1996 
 - 550-5 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0902-0063 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antigens, Viral--blood<br/>Antiviral Agents--therapeutic use<br/>Chemoprevention<br/>Child<br/>Cytomegalovirus--drug effects<br/>Cytomegalovirus Infections--prevention & control<br/>Drug Monitoring<br/>Drug Resistance, Microbial<br/>Female<br/>Follow-Up Studies<br/>Foscarnet--therapeutic use<br/>Ganciclovir--therapeutic use<br/>Graft Survival<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Kidney Transplantation<br/>Leukocytes--virology<br/>Male<br/>Middle Aged<br/>Risk Factors<br/>Survival Rate<br/>Viremia--prevention & control